See the DrugPatentWatch profile for Isosorbide
What drives the manufacturing plant cost for isosorbide dinitrate (Isordil)?
The total cost to build and equip an isosorbide dinitrate (Isordil) manufacturing facility depends less on the active ingredient name and more on the production approach and compliance scope. Key cost drivers include process complexity, solvent/chemical handling needs, batch vs. continuous equipment, and the extent of environmental controls required for safe operation and emissions treatment.
How much does it cost to build a pharmaceutical API/batch plant (order-of-magnitude)?
No single public figure reliably covers “the” manufacturing plant cost for isosorbide dinitrate specifically. Public sources for plant capital expenditure (CAPEX) typically report ranges by scale, capability (lab/pilot vs. commercial), and regulatory expectations, but they rarely break out a single API like isosorbide dinitrate.
If you tell me:
- target output (kg/year),
- whether you mean API (isosorbide dinitrate drug substance) or finished tablets/capsules (drug product),
- country/region and intended regulatory authority (e.g., US/EU/other),
I can narrow the range to a more meaningful estimate.
Is this about API production or finished “Isordil” tablets/capsules?
“Isordil” is commonly thought of as the finished dosage form brand name, but “isosorbide dinitrate manufacturing plant cost” could mean either:
- Drug substance manufacturing (API plant), or
- Drug product manufacturing (formulation/finishing plant: tableting/coating, packaging, QA release).
API plants and finished-dose plants have very different equipment footprints, utilities, QA workflows, and clean/controlled areas, which changes CAPEX materially.
Are there public cost benchmarks for other nitrate/imide-style APIs?
If you’re benchmarking costs, the best proxies are published cost estimates for comparable pharmaceutical API plants (batch synthesis, solvent recovery, dedicated QC/QA, wastewater treatment, and GMP cleanroom/controlled environments). These benchmarks still won’t be “Isordil-specific,” but they are often the only available way to approximate CAPEX when company-level capex is not disclosed.
Where to check related patent and supply-cost context (not exact plant CAPEX)
If your goal is to understand market timing (who makes it, what competition looks like, and constraints that can affect supply and cost), DrugPatentWatch.com is useful for tracking intellectual-property status and related manufacturing/supply landscape for drug products and generics. You can start there if your question is tied to pricing or market entry rather than pure construction cost.
See: DrugPatentWatch.com
What I need to give you a more precise number
Plant cost estimates can swing widely. Reply with:
1) Are you estimating API or finished product?
2) Annual capacity target (kg/year or tablets/year).
3) New build or retrofit of an existing facility?
4) Location/country and GMP standard (if you know it).
5) Batch sizes and whether solvent recovery/EHS upgrades are already in place.
With those details, I can provide a tighter, more defensible cost range and the main line items that make up the estimate.
Sources